<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862338</url>
  </required_header>
  <id_info>
    <org_study_id>C1677</org_study_id>
    <nct_id>NCT04862338</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults</brief_title>
  <official_title>Pharmacodynamics and Tolerance Study of Nicotinamide Mononucleotide (NMN) Supplementation at 400 mg/Day</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seneque SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CEN Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LGD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seneque SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the physiological and/or biological actions of&#xD;
      nicotinamide mononucleotide (NMN-C) in healthy adults receiving a repeated-dose over the&#xD;
      course of 28 days by studying the tolerance and pharmacodynamics of this product.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Exploratory interventional repeated-dose study, open-label, single-arm, single-center</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in NAD+ concentrations in whole blood</measure>
    <time_frame>Day 0, Day 14 and Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NMN concentrations in whole blood</measure>
    <time_frame>Day 0, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline NAD+ metabolite concentrations in plasma</measure>
    <time_frame>Day 0, Day 14 and Day 28</time_frame>
    <description>MeNAM, NAM, DMG, TMG and Homocystein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline NAD+ metabolite concentrations in urine</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
    <description>MeNAM and Me-2-PY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 14 and Day 28</time_frame>
    <description>Evaluation of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the mitochondrial DNA ratio</measure>
    <time_frame>Day 0 and Day 28</time_frame>
    <description>mitochondrial DNA ratio will be assessed in the epithelial cells collected by buccal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood glucose levels</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood lipid levels</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
    <description>Triglycerides, Total Cholesterol, HDL-Cholesterol, LDL-Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Transaminases (ASAT, ALAT, GGT) levels in blood</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Blood cell count</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Bilirubin levels in blood</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Creatinine levels in blood</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine phosphokinase (CPK) levels in blood</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of blood Ionogram</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
    <description>Potassium, Chloride, Sodium levels will be assessed in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Diastolic blood pressure</measure>
    <time_frame>Day -7 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Systolic blood pressure</measure>
    <time_frame>Day -7 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Heart rate</measure>
    <time_frame>Day -7 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of weight</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of body composition</measure>
    <time_frame>Day -7, Day 14 and Day 28</time_frame>
    <description>Body composition will be assessed by impedancemetry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Nicotinamide mononucleotide (NMN-C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide mononucleotide (NMN-C)</intervention_name>
    <description>Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total</description>
    <arm_group_label>Nicotinamide mononucleotide (NMN-C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers should be&#xD;
&#xD;
          -  Men between the ages of 30 and 60 years old&#xD;
&#xD;
          -  With a BMI between 23 and 30 kg/m2&#xD;
&#xD;
          -  With a weight &gt; or = 70kg&#xD;
&#xD;
          -  Giving their free informed consent to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        May not be included in the study Volunteers with&#xD;
&#xD;
          -  a history of allergy to vitamin B3 (niacin or nicotinamide)&#xD;
&#xD;
          -  immunocompromised or suffering from a serious or progressive disease (cardiac,&#xD;
             pulmonary, hepatic, renal, hematologic, neoplastic or infectious)&#xD;
&#xD;
          -  with abnormal results on the screening bioassay (CBC, Transaminases (AST, ALT, GGT),&#xD;
             Bilirubin, Creatinine, CPK, Ionogram, Blood glucose, Hba1c, Lipid profile)&#xD;
&#xD;
          -  having donated blood in the month preceding inclusion,&#xD;
&#xD;
          -  having consumed more than 2 glasses of alcohol per day,&#xD;
&#xD;
          -  being under medication or taking food supplements,&#xD;
&#xD;
          -  having reached the maximum compensation threshold for research involving the human&#xD;
             being as provided for by the regulations or having participated in another biomedical&#xD;
             research project that required blood samples in the previous month,&#xD;
&#xD;
          -  involved in another clinical trial or being in the exclusion period of a previous&#xD;
             clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biomed 21</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerance</keyword>
  <keyword>Pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

